Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002012383-25-001177
Filing Date
2025-02-05
Accepted
2025-02-05 13:23:33
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6606
2 EXHIBIT 24: POWER OF ATTORNEY PowerOfAttorney.txt EX-24 2797
3 EXHIBIT 99: ITEM 7 ITEM7.txt EX-99 603
  Complete submission text file 0002012383-25-001177.txt   12043
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Subject) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-80900 | Film No.: 25592173
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock, Inc. (Filed by) CIK: 0002012383 (see all company filings)

EIN.: 991116001 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)